Eliem Therapeutics, Inc. - נכסים נקיים למניה בודדת ELYM

The book value per common share reflects capital dynamics, where 3.31 represents the current level of the metric. The environmental footprint of Eliem Therapeutics (ELYM) is minimal and limited to formal waste control. Revenues are based on the development of neuropreparations for the therapy of epilepsy and chronic pain. The R&D strategy relies on the full outsourcing of molecule synthesis, which makes the company dependent on external production sites.

Optimizing raw material logistics for Eliem Therapeutics (ELYM) neurological programs minimizes operating expenses, which directly impacts the preservation of equity. The book value per share is calculated as the difference between all assets and liabilities divided by the number of shares outstanding, allowing the investor to use this chart to assess the real value of the company's net assets without market noise.